Zealand Pharma Gets Positive CHMP Opinion For Dasiglucagon For Treatment Of Severe Hypoglycemia In Diabetes From The EMA
Portfolio Pulse from Benzinga Newsdesk
Zealand Pharma (NASDAQ: ZEAL) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its dasiglucagon solution for injection, intended for the treatment of severe hypoglycemia in diabetes patients. This recommendation is a significant step towards obtaining marketing authorization in Europe.
May 31, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zealand Pharma has received a positive opinion from the EMA's CHMP for its dasiglucagon solution for injection, which is a significant step towards marketing authorization in Europe for the treatment of severe hypoglycemia in diabetes patients.
The positive CHMP opinion is a critical milestone for Zealand Pharma as it paves the way for marketing authorization in Europe. This development is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100